Trial Profile
Randomized Phase II Study of Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide Progression
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Docetaxel; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms CABPOSTAAT
- 25 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 09 Aug 2021 Planned End Date changed from 1 Dec 2022 to 30 Sep 2024.
- 09 Aug 2021 Planned primary completion date changed from 1 Dec 2020 to 30 Jul 2024.